Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
-
Source:
Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic
Record details
-
Source:
A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular
Record details
-
Source:
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Record details
-
Source:
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With
Record details
-
Source:
Korean Post-marketing Surveillance for Xeljanz® 5 mg Film-coated Tablets and Xeljanz® 1 mg/mL Oral Solution in Patients With Active pJIA and jPsA
Record details
-
Source:
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisLovell DJ,
Record details
-
Source:
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic
Record details
-
Authors :
Ayse Asena Yekdaneh, Principal Investigator
-
Source:
The Efficiency of Supervised Exercise Program Versus Personalized Mobile-Based Exercise Program in Patients With Juvenile Idiopathic
Record details
-
Source:
Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis:
Record details
-
Source:
Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile
Record details
